10/516500

DT05 Rec'd PCT/PIO 0 2 DEC 2004

oved for use through 04/30/2003. OMB 0651-0031 hark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and _______ nark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number			
Filing Date			
First Named Inventor			
Art Unit			
Examiner Name			
Attorney Docket Number			

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
· · · · · · · · · · · · · · · · · · ·		^{US-} 2003/108628 - A	12 Jun 03	John G. BABISH et al	p1 c1-p1 c2; Ex.6-8
		US-		3.44313	
		US-			, , , <u>, , , , , , , , , , , , , , , , </u>
		US-			
		US-			· ·
		ŪS-			
		US-			
		US-			-
		US-			
-		US-			
		US-			-
		US-			
		US-			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY	, , , , , , , , , , , , , , , , , , , ,	Or Relevant Figures Appear	T ⁶
		WO96/17605 A	13 Jun 96		p6 L7 to p7 L9	
						L
-						<u> </u>
						느

Examiner			Date	
Signature	ì		Considered	
Cignotare			Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/516500

DT05 Rec'd PCT/PT0 0.2 DEC 2004

byed for use through 04/30/2003. OMB 0651-0031
hark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and 1

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO INFORMATION DISCLOSURE		e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
		Application Number	- · · · · · · · · · · · · · · · · · · ·	
		Filing Date		
STATEMENT BY APPLICANT		First Named Inventor		
		Art Unit		
(Use as many sheets as necessary)		Examiner Name		
Sheet	of	Attorney Docket Number		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		H.Y. CHEUNG et al., "Determination of Bioactive Diterpinoids from Andrographis paniculata by Micellar Electrokinetic Chromatography," 930 J. Chromatog. 171-76 (28 Sept 2001) (Elsevier Science, publ.)	
		S.S. HANDA et al., "Hepatoprotective Activity of Andrographolide from Andrographis paniculata Against Carbontetrachloride," 92 Indian J. Med. Res. 276-83 (Aug. 1990) (ISSN: 0971-5916).	•
		P.P. GUPTA et al., "Antiallergic Acivity of Andrographolides Isolated from Andrographis paniculata (Burm. F) wall," 36 Pharma. Biol. 72-74 (Jan. 1998).	
		X-F. ZHANG et al., "Antihyperglycemic and Anti-Oxidant Properties of Andrographis paniculata in Normal and Diabetic Rats," 27 Clin Exper. Pharmacol. and Physiol. (2000).	•
		· ·	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO**: Commissioner for Patents, Washington, DC 20231.